Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 4 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 12 | -1.1524 | -89.3333333333 | 1.29 | 1.34 | 0.121 | 440078 | 0.5449501 | CS |
| 26 | -0.7634 | -84.7280799112 | 0.901 | 3.39 | 0.121 | 1793339 | 1.26467644 | CS |
| 52 | -4.2124 | -96.8367816092 | 4.35 | 7.6699 | 0.121 | 1600119 | 2.23283875 | CS |
| 156 | -70.4624 | -99.8050991501 | 70.6 | 89.566 | 0.121 | 810920 | 6.94869823 | CS |
| 260 | -70.2624 | -99.8045454545 | 70.4 | 486.8 | 0.121 | 752103 | 59.00581471 | CS |
| Nessuna Discussione Trovata |
| Crea Discussione |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
